Conversations on timing, valuation, readiness, and life as a public biotech company.
Going public takes more than strong science. You need the right timing, a credible valuation, and a plan for what comes next.
Join Partners Ross McNaughton and Mike Blankenship for six focused conversations on the decisions that shape a biotech IPO, from readiness and funding to the demands of life as a public company.
Episode 1: Why are biotech IPOs so different?
Biotech investors are funding science, not revenue growth. Discover why clinical milestones, approval prospects, and future commercial potential drive the investment story, and what that means for risk and value.
Episode 2: When is the right time to go public?